SAN DIEGO--(BUSINESS WIRE)--Aethlon Medical, Inc., (OTCBB:AEMD) announced today that its first regulatory submission in the United States will focus on bioterror threats addressed under Project BioShield. In this regard, Aethlon plans to submit a formal Investigational Device Exemption (IDE) to the Food and Drug Administration (FDA) in the first quarter of 2007. The Company has already submitted a preliminary IDE and recently met with FDA officials to present a clinical plan to initiate human studies of its HemopurifierTM, a device designed to remove infectious viral pathogens from circulation.
